Savara Inc. has now cleared its May 20 earnings event — and shorts haven't blinked.
Short interest is essentially unchanged at 13.6% of the free float, flat on the week and up roughly 3% over the past month. That level of conviction is notable: bears held their position through the print, and there is nothing in the borrow market to pressure them out. Cost to borrow is 0.53% APR — cheap enough that carrying a short position costs almost nothing. Availability is wide at 488%, meaning nearly five shares are available to borrow for every one already lent out. That is loosening territory, well above even the year's tightest reading of 125%. The ORTEX short score of 71.2 has been almost immovable for two weeks, signalling that the bearish case here is structural rather than tactical.
The options picture is the sharpest change since the prior notes. The put/call ratio collapsed to 0.67 — more than two standard deviations below its 20-day mean of 1.56 — and has held near that level for two consecutive sessions. That is a dramatic reversal from the 1.75-1.80 range that prevailed for most of May, when traders were stacking put protection ahead of the earnings print. The abrupt flip to call dominance, arriving precisely as the stock fell 7% on the week to $4.72, reads as speculative rather than hedging-driven. Recent earnings history adds context: the May 12 print generated only a +2.9% one-day move before a -7.8% five-day drift, and the March events both closed lower at the one-day and five-day marks. The options market is leaning bullish into the next catalyst; the stock itself is not confirming it.
The Street has been broadly constructive for months, but the most recent analyst changes all date from late 2025 and early 2024. Those moves were uniformly positive — HC Wainwright, Wells Fargo, Oppenheimer and Guggenheim all raised targets in that period, landing in a $9–$11 range. The mean target is now $10.81 against a current price of $4.72, implying more than 100% return potential on paper. The gap is real, but it reflects an August 2026 FDA decision that is almost entirely binary: the bull case rests on Molbreevi approval for autoimmune pulmonary alveolar proteinosis, a confirmed patient population of roughly 5,500, and $224 million in recently raised capital. The bear case is narrow pipeline, uncertain approval, and a stock that has already shed 18% in a month. EPS momentum factor scores of 89 and 90 (30-day and 90-day) are genuinely high, but a pre-revenue biotech's earnings momentum reflects estimate revisions rather than cash generation.
Institutional ownership is concentrated and largely passive at current prices. New Enterprise Associates holds 9.6%, Bain Capital Life Sciences 6.9%, Deerfield 5.4%. None of the top holders made material Q1 changes. State Street added 2.4 million shares as of April 30 — the only notable active accumulation in the top-15 list. Insider activity from March tells a quieter story: CFO David Lowrance executed several small sell transactions at $5.04, totalling around $588,000 across the cluster. With the stock now at $4.72, those sales were modestly well-timed, but the trade sizes are too small to read as a directional signal.
Peer performance this week reinforces the pressure on SVRA. BCYC fell 7.8% on the week, ANNX dropped 9.7%, and LYEL lost 16.2% — the small-cap biotech complex broadly sold off. SVRA's 7% weekly decline is middle-of-pack within that peer group, not a standout underperformer, which at least suggests the selling is sector-driven rather than company-specific this week.
The next hard date is June 4, when Savara's next scheduled event arrives — with the August FDA decision on Molbreevi still the dominant binary. Watch whether the call-heavy options positioning from this week persists or reverts toward put protection; a sustained PCR below 1.0 in the weeks ahead would mark a genuine sentiment shift, while any drift back toward 1.5+ would suggest the bullish flip was short-lived noise ahead of the real catalyst.
See the live data behind this article on ORTEX.
Open SVRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
